Trial
NCT04411082
A Study of IMR-687 in Subjects With Beta Thalassemia
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Cardurion Pharmaceuticals, Inc.
Collaborators
Imara, Inc.
Condition
β Thalassemia
Intervention
IMR-687
Why stopped
IMR-BTL-201demonstrated that while IMR-687 was generally well-tolerated, it failed to show any meaningful benefit in transfusion burden or improvement in most disease-related biomarkers. So, the sponsor has decided to discontinue this study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-15